Hansoh Pharmaceutical Group Company Limited (HNSPF)

Market Cap	26.95B -4.0%
Revenue (ttm)	2.34B +20.5%
Net Income	983.17M +39.7%
EPS	0.16 +37.9%
Shares Out	n/a
PE Ratio	25.02
Forward PE	27.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	900
Open	4.080
Previous Close	4.280
Day's Range	4.080 - 4.080
52-Week Range	3.825 - 5.160
Beta	0.54
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HNSPF

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 9,643
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNSPF

Financial Performance

In 2025, HNSPF's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error